On June 29, CSPC Pharmaceutical rose 3.29% in regular trading, trading at HKD 7.11/share, with turnover of HKD 204 million.

On the news front, CSPC Pharmaceutical recently announced that its core ADC drug SYS6010 in combination with enlonstobart for first-line treatment of driver-gene-negative non-small cell lung cancer has officially commenced a Phase III clinical study in China, with the first subject enrollment planned for July. SYS6010 is an EGFR-targeting antibody-drug conjugate. Prior Phase I/II data demonstrated an objective response rate of 41.8% and a disease control rate of 81.4% among 533 evaluable patients, showcasing favorable anti-tumor activity.

The broader pharmaceutical sector also rallied, with Hengrui Pharma up 4.72%, Luye Pharma up 5.06%, and Hansoh Pharma up 3.21%, providing additional sectoral support to the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)